当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い
。オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル と 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得
Angel Yadav
A late diagnosis, intrinsic drug resistance, and rising interest in discovering novel DNA binding and transcription factor agents as potential therapies in treating ovarian and other gynaecological cancers are all contributing factors to the poor prognosis of ovarian cancer. A deeper knowledge of Sp1's role in the initiation and progression of human cancer is still needed, but it is clear from several prior publications that Sp1 controls the expression of many cellular genes. Sp1 has been discovered to have a dual role, activating and suppressing cellular genes that could otherwise become oncogenes or engage in biological processes like proliferation, differentiation, DNA damage response, apoptosis, and angiogenesis. In fact, there are indications that Sp1 has identical protein variants known as Sp2 and Sp3 support Sp1 in promoting the growth of tumour cells.